Nomura Asset Management Co. Ltd. Acquires Shares of 806 Vaxcyte, Inc. (NASDAQ:PCVX)

Nomura Asset Management Co. Ltd. bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 806 shares of the company’s stock, valued at approximately $92,000.

Other hedge funds also recently made changes to their positions in the company. Riverview Trust Co bought a new stake in Vaxcyte in the 3rd quarter worth approximately $27,000. Blue Trust Inc. increased its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Fifth Third Bancorp purchased a new stake in Vaxcyte during the second quarter valued at $35,000. Meeder Asset Management Inc. lifted its position in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Vaxcyte in the 2nd quarter worth $70,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PCVX has been the topic of several recent research reports. BTIG Research upped their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Leerink Partners raised their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Bank of America raised their price target on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group boosted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Trading Down 0.2 %

Shares of PCVX opened at $87.72 on Monday. Vaxcyte, Inc. has a 1-year low of $53.83 and a 1-year high of $121.06. The company has a 50-day moving average of $101.11 and a 200 day moving average of $91.85.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 7,098 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.21, for a total value of $775,172.58. Following the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at $15,134,431.01. This trade represents a 4.87 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 117,830 shares of company stock worth $12,600,310. Company insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.